Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
Product: Active Ingredient: Dosage Form: New Zealand Sponsor: Manufacturer:
|
Hizentra Normal immunoglobulin 200mg/mL Solution for injection CSL Behring (NZ) Limited CSL Behring AG, Bern, Switzerland
|
Product: Active Ingredient: Dosage Form: New Zealand Sponsor: Manufacturer:
|
Remifentanil-AFT Remifentanil hydrochloride 1.097mg equivalent to Remifentanil 1mg Powder for injection AFT Pharmaceuticals Limited Laboratorio Reig Jofre SA, Barcelona, Spain
|
Product: Active Ingredient: Dosage Form: New Zealand Sponsor: Manufacturer:
|
Remifentanil-AFT Remifentanil hydrochloride 2.194mg equivalent to Remifentanil 2mg Powder for injection AFT Pharmaceuticals Limited Laboratorio Reig Jofre SA, Barcelona, Spain
|
Product: Active Ingredient: Dosage Form: New Zealand Sponsor: Manufacturer:
|
Remifentanil-AFT Remifentanil hydrochloride 5.485mg equivalent to Remifentanil 5mg Powder for injection AFT Pharmaceuticals Limited Laboratorio Reig Jofre SA, Barcelona, Spain
|
Product: Active Ingredient: Dosage Form: New Zealand Sponsor: Manufacturer:
|
Serophene Clomifene citrate 50mg Tablet Pharmacy Retailing (NZ) Limited t/a Healthcare Logistics Teva Pharmaceutical Industries Limited, Kfar Saba, Israel
|
Dated this 4th day of December 2015.
SARAH READER, Acting Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).